Publications

Antimicrobial Activity of Novel β-Lactamase Inhibitor Combinations Tested against Organisms Causing Complicated Urinary Tract Infections in United States Medical Centers. Lead author: HS Sader, presented at ID Week 2019, October 2-6, Washington, DC, USA
Poster #1445

Antimicrobial Activity of Ceftazidime-Avibactam and Comparator Agents Tested against Gram-Negative Organisms Isolated from Patients with Bloodstream Infections in United States Medical Centers (2017-2018). Lead author: CG Carvalhaes, presented at ID Week 2019, October 2-6, Washington, D. C., USA
Poster #129

Cefepime-Zidebactam (WCK 5222) Activity against Clinical Isolates of Non-Fermentative Gram-Negative Bacilli Collected Worldwide in 2018. Lead author: HS Sader, presented at ASM/ESCMID 2019, September 3-6, Boston, MA, USA
Poster 69

Antimicrobial Activity of Cefepime-Zidebactam (WCK 5222) against Clinical Isolates of Carbapenem-Resistant Enterobacterales Collected Worldwide in 2018. Lead author: HS Sader, presented at ASM/ESCMID 2019, September 3-6, Boston, MA, USA
Poster 70

Regional analysis of telavancin and comparator antimicrobial activity against multidrug-resistant Staphylococcus aureus collected in the United States from 2014 through 2016. by Duncan LR, Smith CJ, Flamm RK and Mendes RE. published in J. Glob. Antimicrob. Resist.: in press, 2019.

Frequency of occurrence and antimicrobial susceptibility of bacteria isolated from patients hospitalized with bloodstream infections in United States medical centers (2015-2017). by Sader HS, Castanheira M, Streit JM and Flamm RK. published in Diag. Microbio. Infect. Dis.: in press, 2019.

Antimicrobial Activity of Ceftibuten-Clavulanate When Tested against Clinical Enterobacterales Isolates Collected Worldwide in 2017. Lead author: HS Sader, presented at ASM Microbe 2019, June 20-24, San Francisco, CA, USA
# Sunday-AAR-718

Antimicrobial Activity of Plazomicin Tested against a Worldwide Collection of Enterobacterales Isolated from Patients with Complicated Urinary Tract Infections (2014-2017). Lead author: HS Sader, presented at ASM Microbe 2019, June 20-24, San Francisco, CA, USA
# Sunday-AAR-591

Plazomicin is Active against Enterobacteriaceae Isolates Producing Extended-Spectrum β-Lactamases, Carbapenemases, and Aminoglycoside-Modifying Enzymes from United States (US) Hospitals. Lead author: M Castanheira, presented at ASM Microbe 2019, June 20-24, San Francisco, CA, USA
# Sunday-AAR-596

Antimicrobial Activity of High-Dose Extended-Infusion Cefepime-Tazobactam (WCK 4282) Tested against Gram-Negative Organisms Collected from Medical Centers in the United States and Latin America (2018). Lead author: HS Sader, presented at ASM Microbe 2019, June 20-24, San Francisco, CA, USA
# Sunday-AAR-599

Evaluation of Tebipenem Activity Tested against a Collection of Isogenic Escherichia coli Strains Producing Various Clinically Relevant β-Lactamases. Lead author: LM Deshpande, presented at ASM Microbe 2019, June 20-24, San Francisco, CA, USA
# Saturday-AAR-778

Susceptibility Trends of Ceftolozane-Tazobactam and Comparators When Tested against US Gram-Negative Bacterial Surveillance Isolates Collected from 2012-2018. Lead author: D Shortridge, presented at ASM Microbe 2019, June 20-24, San Francisco, CA USA
#Friday-AAR-538

Ceftobiprole activity when tested against contemporary bacteria causing bloodstream infections in the United States (2016-2017). by Pfaller MA, Flamm RK, Duncan LR, Shortridge D, Smart JI, Hamed KA, Mendes RE and Sader HS. published in Diagn. Microbiol. Infect. Dis., 2019; 94 (3): 304-313

Antimicrobial activity evaluation of tebipenem (SPR859), an orally available carbapenem, against a global set of Enterobacteriaceae, including a challenge set of organisms. by Arends SJR, Rhomberg PR, Cotroneo N, Rubio A, Flamm RK and Mendes RE. published in Antimicrob. Agents Chemother.: in press, 2019.

Activity of tedizolid against gram-positive clinical isolates causing infections in Europe and surrounding areas (2014-2015). by Pfaller MA, Sader HS, Shortridge D, Castanheira M, Flamm RK and Mendes RE. published in J. Chemother. 2019; 13: 1-7

Geographical and temporal variation in the frequency and antimicrobial susceptibility of bacteria isolated from patients hospitalized with bacterial pneumonia: results from 20 years of the SENTRY Antimicrobial Surveillance Program (1997-2016). by Sader HS, Castanheira M, Arends SJR, Goossens H and Flamm RK. published in J. Antimicrob. Chemother. 2019; 74 (6): 1595-1606

Antimicrobial activity of ceftolozane-tazobactam tested against gram-negative contemporary (2015-2017) isolates from hospitalized patients with pneumonia in US medical centers. by Carvalhaes CG, Castanheira M, Sader HS, Flamm RK and Shortridge D. Diagn. Microbiol. Infect. Dis. 2019; 94 (1): 93-102

Activity of ceftolozane-tazobactam and comparators when tested against Gram-negative isolates collected from paediatric patients in the USA and Europe between 2012 and 2016 as part of a global surveillance programme. by Shortridge D, Duncan LR, Pfaller MA and Flamm RK. Int. J. Antimicrob. Agents. 2019; 53 (5): 637-643

Activity of ceftolozane-tazobactam and comparators when tested against Gram-negative isolates collected from paediatric patients in the USA and Europe between 2012 and 2016 as part of a global surveillance programme. by Shortridge D, Duncan LR, Pfaller MA and Flamm RK. Int. J. Antimicrob. Agents. 2019; 53 (5): 637-643

Frequency and Antimicrobial Susceptibility of Bacteria Isolated from Patients Hospitalized with Pneumonia in United States Medical Centers (2017-2018). Lead author: HS Sader, presented at ATS 2019, May 17-22, Dallas, Texas, USA
#8470

Antimicrobial Activity of Plazomicin Tested against Enterobacteriaceae Isolates from European Medical Centres Stratified by Infection Type (2014-2017). Lead author: HS Sader, presented at ECCMID 2019, April 13-16, Amsterdam, Netherlands
#P1873

Antimicrobial Activity of POL7306 Tested against Clinical Isolates of Gram-Negative Bacteria Collected Worldwide. Lead author: HS Sader, presented at ECCMID 2019, April 13-16, Amsterdam, Netherlands
#P1843

Activity of Tedizolid and Comparators against Enterococcus spp. that Include Multidrug-Resistant Clinical Isolates from European and US Medical Centres (2016-2018). Lead author: CG Carvalhaes, presented at ECCMID 2019, April 13-16, Amsterdam, Netherlands
#P1883

Oritavancin Activity against Staphylococcus aureus Clinical Isolates Causing Serious Infections in Hospitalized Patients in Europe (2017-2018). Lead author: CG Carvalhaes, presented at ECCMID 2019, April 13-16, Amsterdam, Netherlands
#P1882

Antimicrobial Activity of Cefepime-Zidebactam (WCK 5222) against Clinical Isolates of Carbapenem-Resistant Enterobacterales Collected Worldwide in 2018. Lead author: HS Sader, presented at ECCMID 2019, April 13-16, Amsterdam, Netherlands
#P1171

Antimicrobial Activity of High-Dose Extended-Infusion Cefepime-Tazobactam (WCK 4282) Tested against Gram-Negative Organisms Collected from Medical Centres in Europe and the Asia-Pacific Region (2018). Lead author: HS Sader, presented at ECCMID 2019, April 13-16, Amsterdam, Netherlands
#P1174

Susceptibility Trends of Ceftolozane-Tazobactam and Comparators When Tested against European Gram-Negative Bacterial Surveillance Isolates Collected from 2012-2018. Lead author: D Shortridge, presented at ECCMID 2019, April 13-16, Amsterdam, Netherlands
#P1189

Cefepime-Zidebactam (WCK 5222) Activity When Tested against Gram-Negative Organisms Isolated from Patients Hospitalized in Europe and the Asia-Pacific Region in 2018. Lead author: HS Sader, presented at ECCMID 2019, April 13-16, Amsterdam, Netherlands
#P1172

Activity of Meropenem-Vaborbactam and Single-Agent Comparators against KPC-Producing Enterobacterales Isolates from European Countries (2016-2018) Stratified by Infection Type. Lead author: M Castanheira, presented at ECCMID 2019, April 13-16, Amsterdam, Netherlands
#L0041

Trends in Antimicrobial Nonsusceptibility of PCV13-Type Streptococcus pneumoniae Pneumonia in Adults in the United States during 2009-2017. Lead author: RE Mendes, presented at IDWeek 2018, October 3-7, San Francisco, CA, USA
#1444

Comparison of Ceftazidime-Avibactam and Ceftolozane-Tazobactam In Vitro Activities when Tested against Gram-Negative Bacteria Isolated from Patients Hospitalized with Pneumonia in US Medical Centers (2017). Lead author: HS Sader, presented at IDWeek 2018, October 3-7, San Francisco, CA USA
#2427

Antimicrobial Activity of Dalbavancin Tested against Gram-Positive Organisms Isolated from Patients with Infective Endocarditis in United States and European Medical Centers. Lead author: HS Sader, presented at IDWeek 2018, October 3-7, San Francisco, CA, USA
#1081

Comparative Activity of Plazomicin and Other Aminoglycosides against Enterobacteriaceae Isolates from Various Infection Sources from Hospitalized Patients in the United States. Lead author: M Castanheira, presented at IDWeek 2018, October 3-7, San Francisco, CA, USA
#1345

Antimicrobial Activity of Ceftolozane-Tazobactam Tested against Contemporary (2015-2017) Gram-Negative Isolates from Patients with Pneumonia in US Medical Centers. Lead author: SJR Arends, presented at IDWeek 2018, October 3-7, San Francisco, CA, USA
#1485

Antimicrobial Activity of Ceftazidime-Avibactam and Comparator Agents Tested against Gram-Negative Organisms Isolated from Complicated Urinary Tract Infections: Results from the International Network for Optimal Resistance Monitoring (INFORM) Program. Lead author: HS Sader, presented at IDWeek 2018, October 3-7, San Francisco, CA, USA
#1523

Global Surveillance: Susceptibility of Ceftolozane-Tazobactam against Escherichia coli, Klebsiella pneumoniae, and Pseudomonas aeruginosa Isolates Collected from Bloodstream Infections in the United States from 2015-2017. Lead author: SJR Arends, presented at IDWeek 2018, October 3-7, San Francisco, CA, USA
#1047

Antimicrobial Susceptibility of Gram-Positive Bacteria Isolated from Patients Hospitalized with Bacteremia in United States and European Medical Centers: Results from the International Dalbavancin Evaluation of Activity (IDEA) Program. Lead author: HS Sader, presented at ID Week 2018, October 3-7, San Francisco, CA, USA.
#1000

Frequency of Occurrence and Antimicrobial Susceptibility of Bacteria Isolated from Patients Hospitalized with Bloodstream Infections in United States Medical Centers (2015-2017). Lead author: HS Sader, presented at IDWeek 2018, October 3-7, San Francisco, CA USA
#1004

Antimicrobial susceptibility of Pseudomonas aeruginosa to ceftazidime-avibactam, ceftolozane-tazobactam, piperacillin-tazobactam, and meropenem stratified by U.S. Census Divisions: Results from the 2017 INFORM Program. by Sader HS, Flamm RK, Carvalhaes CG and Castanheira M. Antimicrob. Agents Chemother.: in press, 2018.

Multidrug-resistant Pseudomonas aeruginosa from sputum of patients with cystic fibrosis demonstrates a high rate of susceptibility to ceftazidime-avibactam. by Atkin SD, Abid S, Foster M, Bose M, Keller A, Hollaway R, Sader HS, Greenberg DE, Finklea JD, Castanheira M and Jain R. published in Infect Drug Resist. 2018; 2018 (11): 1499-1510

The Role of Whole Genome Sequencing on Post-Marketing Surveillance Programs: Results of the INFORM Surveillance Program for Ceftazidime-Avibactam in the United States. Lead author: H Sader, presented at ESCMID/ASM Conference on Drug Development to Meet the Challenge of Antimicrobial Resistance, September 4-7, 2018, Lisbon, Portugal
#107

Activity of dalbavancin and comparator agents against Gram-positive cocci from clinical infections in the USA and Europe 2015-16. by Pfaller MA, Mendes RE, Duncan LR, Flamm RK and Sader HS. published in J. Antimicrob. Chemother. 2018; 73 (10) 2748-2756

Frequency and antimicrobial susceptibility of Gram-negative bacteria isolated from patients with pneumonia hospitalized in ICUs of US medical centres (2015-17). by Sader HS, Castanheira M, Mendes RE and Flamm RK published in J. Antimicrob. Chemother.: in press, 2018.

Antimicrobial Activity of Ceftolozane-Tazobactam Tested against Contemporary (2015-2017) P. aeruginosa Isolates from a Global Surveillance Program. Lead author: D Shortridge, presented at ASM Microbe 2018, June 7-11, Atlanta, GA, USA
# Sunday-393

Antimicrobial Activity of the Novel Siderophore Cehpalosporin GT-1 Tested Alone and Combined with the β-Lactamase Inhibitor GT-055 against Molecularly Characterized Enterobacteriaceae Clinical Isolates. Lead author: HS Sader, presented at ASM Microbe 2018, June 7-11, Atlanta, GA, USA
# Sunday-571

Antimicrobial Activity of Ceftobiprole When Tested against Gram-Positive Cocci Causing Serious Infections (2016-2017): Endocarditis, Diabetic Foot, and Bone/Joint Infections. Lead author: LR Duncan, presented at ASM Microbe 2018, June 7-11, Atlanta, GA, USA
# Sunday-581

Antimicrobial Susceptibility of Pseudomonas aeruginosa to Ceftazidime-Avibactam, Ceftolozane-Tazobactam, Piperacillin-Tazobactam, and Meropenem Stratified by United States Census Divisions: Results from the 2017 INFORM Program. Lead author: HS Sader, presented at ASM Microbe 2018, June 7-11, Atlanta, GA, USA.
# Sunday-388

Activity of Ceftolozane-Tazobactam and Comparators When Tested against Bacterial Isolates Collected from Hematology or Oncology Patients in Europe during 2011-2017 as Part of a Global Surveillance Program. Lead author: D Shortridge, presented at ASM Microbe 2018, June 7-11, Atlanta, GA, USA
# Sunday-394

Antimicrobial Activity of Tebipenem (SPR859) against a Global Challenge Set of Enterobacteriaceae Isolates. Lead author: RE Mendes, presented at ASM Microbe 2018, June 7-11, Atlanta, GA, USA
# Sunday-558

Antimicrobial Activity of Ceftolozane-Tazobactam Tested against Contemporary (2015-2017) Gram-Negative Isolates from Intensive Care Unit Patients with Pneumonia in US Medical Centers. Lead author: D Shortridge, presented at ASM Microbe 2018, June 7-11, Atlanta, GA, USA
# Sunday-392